Contactos
Información
There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast...
mostra más
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
mostra menos
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
Episodios & Posts
Episodios
Posts
Transcrito
17 SEP. 2026 · From billion-dollar drug development bets and looming patent cliffs to drug pricing, patient access and the future of U.S. clinical trials, some of the biggest stories in biotech are connected by one question: what will they mean for the medicines patients ultimately receive?
In this episode of the Making Medicine Podcast, host John Stanford breaks down the stories he’s reading and watching across biotechnology, pharmaceuticals and healthcare policy, and explains why they matter beyond the headlines.
We begin with the enormous financial risk behind pharmaceutical R&D, including the fallout from a failed clinical trial following a multibillion-dollar biotech acquisition. It’s a reminder that the risk of developing a new medicine doesn’t disappear when a smaller biotech is acquired by Big Pharma.
John also examines the approaching patent cliff, as major medicines lose exclusivity and pharmaceutical companies look to M&A and new pipelines for future growth. At the same time, generic drugs and biosimilars could bring lower-cost competition and expanded access for patients.
Then, we turn to drug pricing and patient access. What could the latest pricing agreements mean for the proposed GLOBE and GUARD models? And why can an FDA-approved medicine still remain out of reach while insurers determine coverage and prior authorization requirements?
Finally, John looks at the growing cost and complexity of conducting clinical trials in the United States, why more early-stage trials are moving overseas, and what potential regulatory reforms could mean for America's ability to compete in drug development.
We explore
🔹 The high-stakes financial risk behind pharmaceutical R&D
🔹 How failed clinical trials can affect even the largest drugmakers
🔹 The patent cliff reshaping Big Pharma
🔹 M&A and the search for the next generation of medicines
🔹 GLOBE, GUARD and the changing drug pricing landscape
🔹 Why FDA approval doesn't always mean immediate patient access
🔹 Insurance coverage and prior authorization delays
🔹 Why clinical trials are increasingly moving outside the U.S.
🔹 What regulatory reform could mean for American biotech
Join the Conversation ⬇️
Which issue poses the biggest challenge for the future of American medicine: the cost and risk of R&D, drug pricing, patient access or the growing difficulty of conducting clinical trials in the U.S.? What biotech or pharmaceutical story are you watching right now?
Drop your thoughts in the comments below 👇
We we are reading
CNBC: https://www.cnbc.com/2026/09/08/novartis-novn-del-desiran-drug-trial.html
Endpoints: https://endpoints.news/mercks-top-dealmaker-signals-more-ma-as-keytrudas-patent-cliff-nears/
STAT: https://www.statnews.com/2026/09/02/trump-most-favored-nation-drug-pricing-industry-analysts-skeptical/
STAT: https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/
NYT: https://www.nytimes.com/2026/09/04/opinion/clinical-trials-drugs-science.html
👍 Subscribe to the Making Medicine Podcast for more conversations about the science, business and policies shaping how medicines are discovered, developed and delivered to patients.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Biotech News: What We’re Reading
00:59 Novartis, Avidity & the Risk of Pharma R&D
04:05 Big Pharma’s Patent Cliff & M&A Strategy
06:49 GLOBE, GUARD & Most Favored Nation Drug Pricing
08:37 FDA Approval vs. Patient Access to Cancer Drugs
11:41 Why U.S. Clinical Trials Are Moving Overseas
14:17 Closing
DISCLAIMER: We're reporting on and discussing developments in medicine, biotechnology and healthcare policy, not making medical recommendations. For personal health questions, always consult a qualified healthcare professional.
#Biotech #DrugPricing #DrugDevelopment #PatientAccess #MakingMedicine
Transcrito
10 SEP. 2026 · Why does a small molecule medicine get nine years on the market before Medicare negotiation while a biologic gets 13? And what does that four-year difference mean for the medicines that do get developed?
For 9/13 Day, the Making Medicine Podcast is revisiting some of our most important conversations about the pill penalty and its impact on biotech investment, drug development and patients.
Under the Inflation Reduction Act, small molecule medicines become eligible for Medicare drug price setting after nine years, compared with 13 years for biologics. That difference may sound small, but investors and biotech leaders argue it can significantly change the economics of developing a new medicine.
In this special episode, host John Stanford explains why some small molecule investment continues despite the pill penalty, why 13 years isn't a “magic number,” and why the later years of a medicine's life can be so important to recovering the enormous cost and risk of drug development.
We also revisit conversations with investors, scientists and industry leaders who explain how the 9-versus-13-year distinction factors into real-world decisions about which technologies, companies and medicines receive investment.
Plus, we look at the EPIC Act, legislation supported by Incubate that would eliminate the disparity by giving small molecule medicines and biologics the same 13-year timeline. The concern isn't parity for its own sake, the years between nine and thirteen can be some of the most commercially important in a medicine's lifecycle. Shortening that runway for biologics wouldn't fix the underlying incentive problem; it would just extend it to another class of medicines.
The question isn't simply whether nine years sounds like enough. It's whether public policy is unintentionally encouraging scientists and investors to pursue one type of medicine over another, and what that could ultimately mean for patients.
We explore
🔹 What the “pill penalty” actually means
🔹 Why small molecules receive nine years while biologics receive 13
🔹 Why some investors still fund small molecule medicines
🔹 Why the later years of a drug's commercial life matter
🔹 How the pill penalty can influence biotech investment decisions
🔹 Why small molecules remain important to cancer and other diseases
🔹 What Incubate's Life Science Investment Tracker is finding
🔹 Why investors say policy can influence small molecule vs. biologic development
🔹 How the EPIC Act would address the 9-versus-13-year disparity
🔹 What changing investment incentives could ultimately mean for patients
Join the Conversation ⬇️
Do you think small molecule medicines and biologics should receive the same timeline before Medicare negotiation?
Should policymakers consider how drug pricing policies affect investment decisions years before a medicine reaches patients?
Could the 9-versus-13-year distinction change which medicines ultimately get developed?
Drop your thoughts in the comments below 👇
👍 Subscribe to the Making Medicine Podcast for more conversations about the science, policy and investment shaping the future of American medicine.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Why Invest for 9 Years When You Can Get 13?
00:21 What Is the Pill Penalty?
03:32 How the Pill Penalty Changes Biotech Investment
07:49 Why Do Biologics Get 13 Years?
09:16 Why Years 9–13 Matter for Drug Revenue
12:22 Why Small Molecule Drugs Still Matter
19:31 9/13 Day and the EPIC Act
21:24 The Data on Declining Small Molecule Investment
24:33 How Price Controls Affect Biotech Investment
34:40 Do Investors Really Favor Biologics?
36:35 Closing
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#PillPenalty #biotech #drugdevelopment #drugpricing #MakingMedicine
Transcrito
3 SEP. 2026 · A new pancreatic cancer medicine could double survival time. Its annual list price? $480,000. That number is getting lots of attention, but the economics of bringing breakthrough medicines to patients are more complex than a single price tag can convey.
After more than a decade of development and billions of dollars invested, Revolution Medicines has brought a new treatment to patients with metastatic pancreatic cancer, one of the deadliest forms of cancer. Yet much of the public discourse has focused on its $480,000 annual list price. In this episode of the Making Medicine Podcast, host John Stanford examines what that price actually represents and what it can tell us about the costs, risks, and economics of medical innovation.
What does it really cost to develop a breakthrough cancer medicine? How much of a drug's list price does the manufacturer actually receive? What role do insurers, rebates and payer negotiations play? And when a medicine clearly works, who should ultimately be responsible for ensuring patients can access it?
John examines the economics behind the headline, including Revolution Medicines' reported billions in accumulated losses, the enormous cost and risk of oncology drug development, and the complicated insurance system standing between an approved medicine and the patients who need it.
Plus, we break down a packed month of biotech and pharmaceutical policy news in Washington: new Most Favored Nation drug pricing agreements, the CMS GLOBE and GUARD models, U.S. biotech deals involving China, the fight over America's biotechnology competitiveness, and the nomination of Dr. Heidi Overton to lead the FDA.
We also look ahead to the next FDA user fee agreement and what changes could mean for smaller, venture-backed biotechnology companies before closing with our FDA Approvals Roundup and the latest medicines reaching patients.
We explore
🔹 Why a new pancreatic cancer drug carries a $480,000 list price
🔹 What Revolution Medicines invested before reaching its first approval
🔹 Why drug list prices don't necessarily reflect what manufacturers receive
🔹 Insurance, rebates, and patient access
🔹 The economics and risks behind developing new cancer medicines
🔹 Most Favored Nation drug pricing and new White House agreements
🔹 CMS GLOBE and GUARD drug pricing models
🔹 U.S. biotech investment, China and national security
🔹 The nomination of Dr. Heidi Overton to lead the FDA
🔹 What the next FDA user fee agreement could mean for biotech
🔹 New FDA approvals across cancer, rare disease and other conditions
Join the Conversation ⬇️
When a new medicine costs billions of dollars and more than a decade to develop, how should we determine what a fair price looks like?
Should the debate over a $480,000 cancer drug focus more on the manufacturer’s list price or what patients and insurers ultimately pay?
How can America make breakthrough medicines accessible to patients while still encouraging investment in the next generation of treatments?
Drop your thoughts in the comments below👇
Read Incubate's comments on GLOBE and GUARDhttps://www.incubatecoalition.org/post/incubate-submits-comments-on-globe-guard-comments
👍 Subscribe to the Making Medicine Podcast for more conversations about the science, policy, investment and innovation shaping the future of American medicine.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Why Does a Cancer Drug Cost $480,000?
00:24 Welcome to Making Medicine
01:08 New White House Drug Pricing Deals
03:04 $20 Billion in U.S. Pharmaceutical Investment
03:55 What Drug Price Controls Could Mean for Biotech
06:15 CMS GLOBE and GUARD Explained
08:17 Congress Takes Aim at Biotech Deals With China
10:09 Is China Becoming a Biotech Superpower?
11:03 The Truth Behind the $136 Billion China Biotech Number
13:20 U.S. Biotech, China and National Security
15:36 Who Will Lead the FDA?
17:18 What's Next for FDA and Biotech?
20:00 A Breakthrough in Pancreatic Cancer
22:49 The Economics Behind Revolution Medicines
26:32 What Does the $480,000 Drug Price Really Mean?
27:51 Will Insurers Cover a Drug That Works?
30:21 Why the List Price Isn't the Whole Story
31:23 FDA Approvals Roundup
34:36 Closing
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#biotech #drugpricing #pancreaticcancer #pharmaceuticals #fda #MakingMedicine
Transcrito
27 AGO. 2026 · 🇺🇸 Artificial intelligence is reshaping biotech, drug discovery and medicine. But how much of the AI revolution is real, how much is hype, and what could it mean for the future of American medicine?
In Part 6 of our How America Makes Medicine series, host John Stanford sits down with physician-scientist and venture capitalist Patrick Malone to explore how AI and machine learning could transform drug development, biotech investing and the way new medicines reach patients.
Could AI agents and computational drug discovery allow a handful of people, or even one founder, to build a billion-dollar biotech company? Can better access to clinical trial and regulatory data accelerate innovation? And if AI makes drug discovery faster and cheaper, can it overcome the industry's biggest bottleneck: clinical trials?
John and Patrick also examine the future of U.S. biotechnology, FDA modernization, venture capital, China's growing biotech capabilities and what America must do to remain a global leader in life sciences.
Plus, John breaks down the latest biotech headlines and traces the evolution of AI in medicine, from early computer models and the Human Genome Project to AlphaFold and today's AI-driven drug discovery platforms.
What happens next could reshape how America makes medicine. It’s an important conversation about the future of biotech you can’t afford to miss.
We explore
🔹 What's real, and overhyped, about AI drug discovery
🔹 The rise of smaller, AI-powered biotech companies
🔹 Why clinical trials remain a critical bottleneck
🔹 The widening "Valley of Death" for biotech innovation
🔹 Clinical and regulatory data's role in the AI revolution
🔹 FDA modernization and Operation Trial Blazer
🔹 Venture capital and the future of drug development
🔹 U.S. biotechnology leadership and competition with China
🔹 What the next generation of American biotech could look like
This episode is part of How America Makes Medicine, a seven-part series exploring the people, science, institutions, and business decisions behind 250 years of American pharmaceutical innovation.
From research universities and biotechnology startups to pharmaceutical manufacturers, investors, regulators and patients, the series examines how America's medicine ecosystem was built and what it will take to keep innovating.
Join the Conversation ⬇️
How much do you think AI will change the way new medicines are discovered and developed over the next decade?
Could a one-person or small-team biotech really become a billion-dollar company, or is the industry too complex for that model?
What should America prioritize most to remain a global leader in biotechnology: AI and data, faster drug development, more investment, or stronger domestic capabilities?
Drop your thoughts in the comments below👇
👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part series celebrating 250 years of American pharmaceutical innovation.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Could One Person Build a Billion-Dollar Biotech?
00:17 How America Will Make Medicine
01:36 This Week in Biotech: Headlines
03:34 The History of AI in Drug Discovery
10:08 Meet Patrick Malone: From Medicine to Venture Capital
15:07 AI Drug Discovery: What's Real and What's Hype?
17:32 The Billion-Dollar Biotech of the Future
21:51 What's Changing in Biotech Venture Capital?
23:49 Is Biotech's Valley of Death Getting Wider?
25:36 Does America Have the Data AI Needs?
29:28 Why Biotech Needs a Stronger Voice in Washington
32:30 Faster Drug Development and Operation Trial Blazer
35:04 U.S. Biotech, China and the Future of Competition
45:58 Closing
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#ArtificialIntelligence #Biotechnology #DrugDiscovery #FutureOfMedicine #MakingMedicine
Transcrito
20 AGO. 2026 · 🇺🇸 Venture capital helped build America's biotech industry, but what happens when that capital stops flowing?
In Episode 5 of the How America Makes Medicine series, John Stanford sits down with Michael Rome, Managing Director and Head of Therapeutics Investing at Foresite Capital, to explore the role of biotech venture capital in building America's drug development ecosystem.
The episode examines the history of venture capital and biotech investing, tracing how America's unique approach to financing high-risk science helped transform academic discoveries into companies and, ultimately, new medicines. From early investment models to the rise of venture-backed biotechnology companies, the history reveals how investors began taking risks on scientific ideas that traditional pharmaceutical companies were often unwilling or unable to pursue.
John and Michael then explore how biotech investors evaluate companies, scientific opportunities, and emerging drug-development technologies today. Their conversation covers early-stage biotech investing, specialist versus generalist investors, biotech IPOs, mergers and acquisitions, capital formation, and the role investors play in determining which scientific ideas move from the laboratory into clinical development.
The discussion also examines how drug pricing policy, FDA policy, government regulation, and uncertainty in Washington can influence investment decisions and the availability of capital for emerging biotech companies. John and Michael discuss the importance of maintaining a strong U.S. innovation ecosystem as biotechnology becomes increasingly global, including competition for scientific talent, investment, and drug development between the United States and China.
What happens to American drug development if investors become less willing to take scientific risks?
We explore
🔹 The history of venture capital and American biotech innovation
🔹 Michael Rome and the role of therapeutics investing
🔹 How venture capital helps fund scientific discovery
🔹 Biotech startups and early-stage drug development
🔹 How investors evaluate biotech companies and scientific opportunities
🔹 Specialist versus generalist biotech investors
🔹 Biotech IPOs, mergers and acquisitions
🔹 Capital formation and the future of biotech investment
🔹 Drug pricing policy and its impact on biotech investment
🔹 FDA policy, government regulation and investment uncertainty
🔹 America's biotechnology ecosystem and global competitiveness
🔹 Competition for scientific talent, investment and innovation
🔹 The role of venture capital in bringing new medicines to patients
This episode is part of How America Makes Medicine, a seven-part series exploring the people, science, institutions, and business decisions behind 250 years of American pharmaceutical innovation.
From research universities and biotechnology startups to pharmaceutical manufacturers, investors, regulators and patients, the series examines how America's medicine ecosystem was built and what it will take to keep innovating.
Join the Conversation⬇️
What do you think is the biggest challenge facing biotech investors today?
How important is venture capital to developing the next generation of medicines?
Can the United States maintain its leadership in biotech as global competition increases?
Drop your thoughts in the comments below👇
👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part series celebrating 250 years of American pharmaceutical innovation.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Introduction: Venture Capital and the Drug Development Pipeline
01:36 Headlines: mRNA Cancer Vaccine and the FDA
05:15 History: How Venture Capital Became Part of Medicine
07:29 Genentech and the Birth of Venture-Backed Biotech
09:30 Michael Rome's Path from Scientist to Biotech Investor
12:40 Why Los Angeles Is Emerging as a Biotech Hub
13:32 Inside Foresight Capital's Biotech Investment Strategy
16:00 A Day in the Life of a Biotech VC
19:15 Don't Chase the Headlines: How Investors Evaluate Biotech Data
21:30 Specialist vs. Generalist Capital in Biotech
24:51 What Happens to Medicine Without Venture Capital?
27:15 Washington's Growing Influence on Biotech Investment
30:44 The IRA and the "Pill Penalty"
33:00 China, Biotech Licensing, and Bringing Innovation to the U.S.
36:53 How Biotech Capital Gets Recycled in America
39:16 Inside a $2 Billion Biotech Exit
43:46 Closing: The Day in the Life of a VC
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#HowAmericaMakesMedicine #biotech #venturecapital #drugdevelopment #pharmaceuticalinnovation
Transcrito
13 AGO. 2026 · 🇺🇸 Why does so much pharmaceutical innovation come from small biotech companies? And how do different parts of America's medicine ecosystem work together to turn scientific discoveries into medicines for patients?
In this episode of How America Makes Medicine, John Stanford sits down with Dr. Jeremy Levin, a longtime pharmaceutical and biotechnology leader, to explore the interconnected ecosystem behind American drug innovation and the complementary roles of small biotech companies and larger pharmaceutical manufacturers.
Levin's career includes leadership roles at Novartis, Bristol-Myers Squibb, Teva Pharmaceuticals, and Ovid Therapeutics. He also discusses the "String of Pearls" strategy, a targeted approach to acquisitions and partnerships designed to strengthen pharmaceutical pipelines and advance promising innovations.
The conversation examines why small biotech companies are an important source of innovation, while larger pharmaceutical manufacturers contribute scientific expertise, capital, manufacturing capabilities, regulatory experience and global infrastructure. Together, these different strengths help move discoveries from research and development toward patients.
The episode also explores drug pricing policy, Most Favored Nation pricing, the Inflation Reduction Act, venture capital, pharmaceutical regulation and biotech investment, including how policy uncertainty can affect the development of future medicines.
Levin also discusses China's growing biotechnology capabilities and America's global innovation advantage, arguing that the United States must continue strengthening its research infrastructure, technical expertise and investment environment to remain a leader in biotechnology and drug development.
We explore:
🔹 Small biotech and pharmaceutical innovation
🔹 Small biotech and larger pharmaceutical manufacturers
🔹 Jeremy Levin and the "String of Pearls" strategy
🔹 Bristol-Myers Squibb and biotech acquisitions
🔹 Drug discovery and development
🔹 Venture capital and biotech investment
🔹 Drug pricing and pharmaceutical policy
🔹 Most Favored Nation pricing and the Inflation Reduction Act
🔹 NIH, FDA and America's research ecosystem
🔹China's growing role in biotechnology
🔹 America's global biotechnology advantage
🔹 Innovation, investment and patient access
How America Makes Medicine is a seven-part series exploring the people, science, institutions and business decisions behind 250 years of American pharmaceutical innovation.
From research universities and biotechnology startups to pharmaceutical manufacturers, investors, regulators and patients, the series examines how America's medicine ecosystem was built and what it will take to keep innovating.
Technical note: Near the end of the episode, Dr. Levin loses his internet connection and continues the conversation by phone. His video is temporarily replaced with a still image while the conversation continues.
Watch the full episode and let us know your thoughts below ⬇️
What role should small biotech companies play in America's future drug-development strategy?
Can the United States maintain its biotechnology advantage as global competition increases?
Drop your thoughts in the comments below 👇
👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part documentary series celebrating 250 years of American pharmaceutical innovation.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Jeremy Levin and America's Biotech Innovation Engine
00:38 Jeremy Levin's Career in Pharmaceutical Innovation
03:04 The "String of Pearls" Strategy
05:37 The Birth of America's Biotechnology Industry
07:19 Why Patients Drive Drug Development
11:56 How Biotech Acquisitions Strengthen Drug Pipelines
16:20 Small Biotech and Larger Pharmaceutical Manufacturers
20:20 Why Small Biotech Drives Drug Innovation
21:43 Drug Pricing, Policy and Biotech Investment
28:10 How Policy Uncertainty Affects Drug Development
38:35 Biotech in the Balance: America's Innovation Advantage
40:57 NIH, FDA and America's Research Ecosystem
42:20 China and the Global Biotechnology Race
46:58 Protectionism and the Future of Innovation
49:09 How America Can Compete Through Innovation
50:44 The Football Analogy: Who Will Win?
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#HowAmericaMakesMedicine #MakingMedicine #biotech #drugdevelopment #pharmaceuticalinnovation #lifesciences #medicalinnovation #biotechnology
Transcrito
6 AGO. 2026 · 🇺🇸 Every breakthrough medicine begins with a scientific discovery. But turning that discovery into a *treatment* that reaches patients*requires navigating one of the most challenging journeys in medicine.
Before a new therapy can change lives, promising science must attract funding, become a startup company, navigate years of development, survive the *"Valley of Death,"* scale manufacturing, and ultimately secure the support of larger pharmaceutical companies capable of bringing lifesaving treatments to patients around the world.
In Episode 3 of How America Makes Medicine, John Stanford sits down with Sheila Mikhail, serial biotech entrepreneur and co-founder of AskBio, Bamboo Therapeutics, Chatham Therapeutics, and M34, to explore what it really takes to build a biotech company from groundbreaking science. Drawing from decades of experience gene therapy, Sheila shares how perseverance, early-stage investment, scientific innovation, and smart partnerships help move promising discoveries from university laboratories to patients.
We explore:
🔹 The real journey from scientific discovery to approved medicine
🔹 Why the "Valley of Death" threatens breakthrough innovations
🔹 How SBIR funding helps launch biotech startups
🔹 Why early-stage companies eventually partner with Big Pharma
🔹 The future of gene therapy and Alzheimer's research
🔹 Manufacturing innovation and lowering the cost of advanced medicines
🔹 America's biotechnology ecosystem and global competition
🔹 How AI could transform drug development
One of the conversation's strongest themes is that great science alone is never enough. Every successful medicine requires scientists, entrepreneurs, investors, regulators, and pharmaceutical companies working together to move discoveries from the laboratory to patients.
This episode is part of How America Makes Medicine, a special editorial series from the Making Medicine Podcast exploring the people, policies, discoveries, and innovations shaping the future of American medicine.
Watch the full episode and let us know your thoughts below ⬇️
Why do you think so many promising medical discoveries never become medicines?
Should America invest more in early-stage biotechnology?
What breakthrough technology will define the next generation of medicine?
Drop your thoughts in the comments below 👇
👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part documentary series celebrating 250 years of American pharmaceutical innovation.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps
00:00 Patients Don't Care Where Medicine Comes From
00:35 Why Every Medical Breakthrough Needs an Entrepreneur
01:54 The Bayh-Dole Act and the Birth of Modern Biotech
04:40 How AskBio Was Founded
07:05 Betting on Gene Therapy Before Anyone Else
11:10 Building Biotech Companies Without Venture Capital
16:30 Why SBIR Funding Saves Medical Innovation
19:10 Is China Winning the Biotech Race?
24:20 Lower Drug Costs Through Better Innovation
26:10 AI, Gene Therapy & the Future of Drug Development
34:00 Making Gene Therapies Affordable Worldwide
39:10 When Should a Startup Partner With Big Pharma?
43:40 Lessons From Selling AskBio to Bayer
50:15 AI, Innovation & The Next Generation of Medicine
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#HowAmericaMakesMedicine #biotech #genetherapy #drugdiscovery #medicalinnovation #healthcarepolicy #sbir #biotechnology #pharmaceuticalinnovation #innovation
Transcrito
30 JUL. 2026 · 🇺🇸 Every breakthrough medicine starts somewhere. Discover how research universities, NIH funding, and American innovation change lives.
Every new medicine’s journey begins long before it reaches a patient. In Episode 2 of our How America Makes Medicine series, John Stanford sits down with Kate Hudson of the Association of American Universities (AAU) to explain why research universities are one of America's greatest strategic advantages.
From federally funded NIH research to technology transfer, startups, biotechnology companies, and ultimately life-saving medicines, this conversation reveals the innovation pipeline that has powered American pharmaceutical leadership for generations.
The discussion explores why curiosity-driven research matters, how the Bayh-Dole Act transformed commercialization and why America faces increasing competition from China in scientific research and biotechnology.
Whether you're interested in biotech, healthcare policy, drug discovery, academic research, or the future of American competitiveness, this episode explains why basic research remains one of the country's most important long-term investments.
Topics include:
🔹 NIH and NSF research funding
🔹 Research universities and scientific discovery
🔹 Technology transfer and commercialization
🔹 Drug discovery and pharmaceutical innovation
🔹 Bayh-Dole Act
🔹 mRNA vaccines
🔹 Basic research versus applied research
🔹 America's biotechnology ecosystem
🔹 Competition with China
🔹 The future of scientific innovation
This episode is part of How America Makes Medicine, a seven-part series celebrating 250 years of American pharmaceutical innovation.
If you're passionate about biotechnology, pharmaceutical innovation, healthcare policy, scientific discovery, or the history of medicine, subscribe to the Making Medicine Podcast and follow How America Makes Medicine as we continue telling the story behind the medicines that have shaped our world.
Watch the full episode and let us know your thoughts below ⬇️
Why should taxpayers invest in basic scientific research?
Is America doing enough to maintain leadership in biotechnology?
What breakthrough medicine do you think will define the next 25 years?
Drop your thoughts in the comments below 👇
👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part documentary series celebrating 250 years of American pharmaceutical innovation.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps:
00:00 Why Research Universities Matter to American Pharmaceutical Innovation
01:28 Meet Kate Hudson of the Association of American Universities
04:20 The History of America's Research Universities
08:32 Why Universities Drive Scientific Discovery
10:42 NIH Funding, NSF Grants & Basic Research Explained
14:09 Why the Free Market Alone Won't Create Medical Breakthroughs
16:05 mRNA Vaccines Took Decades of Research
18:55 The True Return on Investment in Scientific Research
21:18 Why Scientific Talent Matters More Than Ever
24:10 OMB Proposal, NIH Grants & Research Stability
29:20 Why Uncertainty Slows Drug Discovery
33:12 Technology Transfer & How Universities Create Biotech Startups
35:40 Crossing the Valley of Death in Drug Development
38:10 Bayh-Dole, China & America's Innovation Advantage
41:58 Episode Wrap Up & Next Episode Preview
DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#HowAmericaMakesMedicine #biotech #drugdiscovery #ResearchUniversities #innovation #healthcarepolicy #science #pharmaceuticalinnovation #technologytransfer
Transcrito
23 JUL. 2026 · 🇺🇸 How America Makes Medicine begins with the remarkable story of 250 years of American pharmaceutical innovation.
Welcome to How America Makes Medicine, a new seven-part series from the Making Medicine Podcast celebrating 250 years of American pharmaceutical innovation.
As the United States celebrates its *250th anniversary, this inaugural episode of the series traces the extraordinary journey from the medicine chest of 1776 to today's breakthrough therapies. Throughout How America Makes Medicine, we'll explore the discoveries, scientists, entrepreneurs, manufacturers, regulators, and patients who transformed medicine from simple remedies into one of humanity's greatest achievements.
Part I of How America Makes Medicine follows some of the most significant milestones in pharmaceutical history, from the commercialization of insulin and the biotechnology revolution to monoclonal antibodies, HIV therapies, precision medicine, the Human Genome Project, gene therapy, and mRNA vaccines. Along the way, we examine why manufacturing, scientific collaboration, and decades of research are just as important as the discoveries themselves in bringing new medicines to patients.
This episode covers
🔹 How insulin changed diabetes from a fatal diagnosis into a manageable disease
🔹 The biotechnology revolution and recombinant DNA
🔹 The birth of modern biotech
🔹 Monoclonal antibodies and targeted medicine
🔹 HIV therapies and one of medicine's greatest public health successes
🔹 The Human Genome Project and precision medicine
🔹 Gene therapy and cell therapy
🔹 The decades of research behind mRNA vaccines
🔹 Why manufacturing, regulation, and scientific collaboration remain essential to the next generation of medical breakthroughs
Throughout How America Makes Medicine, we explore not only breakthrough discoveries but also the people, companies, manufacturers, researchers, regulators, and patients who made those discoveries possible. This seven-part documentary series celebrates 250 years of American pharmaceutical innovation and highlights how curiosity, entrepreneurship, manufacturing excellence, and scientific persistence continue to improve lives around the world.
If you're passionate about biotechnology, pharmaceutical innovation, healthcare policy, scientific discovery, or the history of medicine, subscribe to the Making Medicine Podcast and follow How America Makes Medicine as we continue telling the story behind the medicines that have shaped our world.
Catch the full episode and Join the Conversation ⬇️
Which medical breakthrough do you think has had the greatest impact on humanity?
What innovation do you believe will define the next generation of medicine?
Which chapter of pharmaceutical history would you like us to explore in a future episode?
Drop your thoughts in the comments below 👇
👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part documentary series celebrating 250 years of American pharmaceutical innovation.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps:
0:00 250 Years of American Pharmaceutical Innovation | Introduction
0:52 Benjamin Rush & Colonial Medicine | America's First Medical Innovator
2:32 American Apothecaries to Modern Drug Manufacturing
4:05 The U.S. Patent System & Pharmaceutical Innovation
5:06 FDA History | Frances Kelsey, Drug Safety & Public Trust
6:23 Eli Lilly, Insulin & the Birth of Modern Pharmaceutical Manufacturing
8:53 The Biotechnology Revolution | Recombinant DNA & Genentech
11:32 Monoclonal Antibodies, HIV Therapies & Modern Biopharmaceuticals
13:15 The Human Genome Project, Precision Medicine & Gene Therapy
14:45 mRNA Vaccines | Why Medical Breakthroughs Take Decades
16:08 The Five Pillars of American Pharmaceutical Innovation
17:35 Clinical Trials, Patients & The Next 250 Years of Medicine
19:40 How America Makes Medicine | Episode 2 Preview & Subscribe
DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#HowAmericaMakesMedicine #pharmaceuticalinnovation #biotechnology #healthcareinnovation #humangenomeproject
Transcrito
16 JUL. 2026 · 🇺🇸 FDA leadership, China's growing role in clinical trials, NIH research, and biotechnology innovation are shaping the future of American medicine.
This week on the Making Medicine Podcast, John Stanford breaks down the latest developments in the search for the next FDA Commissioner, including the three reported finalists: Dr. Heidi Overton, White House health policy adviser; Dr. Jeffrey Vacirca, oncologist and CEO of New York Cancer & Blood Specialists; and Dr. Stephen Ferrara, Deputy Assistant Secretary of Defense for Health Affairs and former CIA Chief Medical Officer. John explores what the next FDA leader could mean for regulatory modernization, drug development, and the future of American biotechnology.
This episode covers:
🔹 The latest FDA Commissioner search and what the three finalists could mean for the agency
🔹 Congressional hearings on FDA modernization and biomedical innovation
🔹 China's rapid expansion in global clinical trials and growing biotech competitiveness
🔹 Patent eligibility reform, intellectual property protections, and the future of biotech investment
🔹 NIH research funding, research security, and protecting American scientific leadership
🔹 FDA Approvals Corner featuring new therapies from Rigel Pharmaceuticals, BeOne Medicines, AstraZeneca, Gilead Sciences, AbbVie, Haisco Pharmaceutical Group, Shionogi, Wockhardt, Bayer, GSK, and Viridian Therapeutics
From FDA leadership and congressional hearings to intellectual property, research security, and global competition with China, this episode examines the policy decisions shaping the future of biomedical innovation. John also highlights why protecting NIH-funded research, modernizing the FDA, and strengthening America's innovation ecosystem remain essential to delivering the next generation of medicines and improving patient access.
The episode concludes with another edition of FDA Approvals Corner, celebrating newly approved therapies across oncology, infectious disease, cardiovascular medicine, rare diseases, anesthesia, and diagnostic imaging, highlighting the continued progress being made for patients around the world.
Watch the full episode and Join the Conversation ⬇️
Who should lead the FDA?
How should America compete with China's growing biotech industry?
What role should NIH-funded research play in future drug development?
Drop your thoughts in the comments below 👇
👍 Like and subscribe for more conversations on biotechnology, healthcare policy, FDA news, clinical trials, pharmaceutical innovation, and life sciences.
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps:
00:00 Why American Biotech Matters
01:35 FDA Leadership Search
03:14 FDA & China Hearings
05:13 Clinical Trial Competition
06:25 Patent Reform Explained
07:52 NIH Research Security
08:58 Why NIH Funding Matters
09:19 FDA Approvals Corner
11:32 July FDA Outlook
DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
#fda #biotech #healthcarepolicy #clinicaltrials #NIH
There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast...
mostra más
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
mostra menos
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
Información
| Autor | Making Medicine Duality |
| Organización | Making Medicine Podcast |
| Categorías | Salud y forma física |
| Página web | www.spreaker.com |
| contact@dualityent.com |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
